# REACT-IrNPC (NCT04448522)

> Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: chemotherapy-sensitive stage II-III nasopharyngeal carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04448522
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Sun Yat-sen University
- Conditions: Nasopharyngeal Carcinoma; Radiotherapy; Chemotherapy
- Interventions: reduced dosage IMRT; conventional dosage IMRT
- Enrollment: 508
- Primary outcome: Progress-free survival (PFS)

## Indexed commentary on REACT-IrNPC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=react-irnpc-nct04448522